- Home
- SOPH vs MGTX Comparison
SOPH vs MGTX Comparison
Compare SOPH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | MGTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 610.1M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SOPH | MGTX |
|---|---|---|
| Price | $4.87 | $10.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $22.86 |
| AVG Volume (30 Days) | 84.7K | ★ 637.8K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $23.09 | $94.60 |
| Revenue Next Year | $19.57 | $22.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $2.58 | $5.02 |
| 52 Week High | $5.70 | $9.88 |
Technical Indicators
Market Signals| Indicator | SOPH | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 78.10 |
| Support Level | $4.54 | $7.03 |
| Resistance Level | $5.30 | N/A |
| Average True Range (ATR) | 0.27 | 0.66 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 59.42 | 96.60 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.